论文部分内容阅读
目的 :探讨转录因子Oct4和Sox2的表达在肺癌患者中表达及与肺癌病理分级和临床分期的相关性。方法 :选取2010年3月2012年5月就诊于我院确诊的肺癌患者115例,对比患者肺部癌症病灶内的转录因子Oct4和Sox2的表达规律,分析两种因子与患者癌症分级及分期关系。结果 :115例患者中Oct4表达率为42.61%(49),Sox2表达率为55.65%(64)。在115例肺癌组织检测中,Oct4、Sox2表达均为阳性者为26.96%(31),两种表达因子均为阴性者见12.17%(14),Oct4表达患者5年生存率8.16%,Sox2表达患者5年生存率14.06%,差异显著。结论 :转录因子Oct4和Sox2在肺癌病灶内表达度高,与癌灶发生、发展及转移密切相关,可作为判断患者治疗效果及预后的重要指标。
Objective: To investigate the expression of transcription factors Oct4 and Sox2 in patients with lung cancer and their relationship with the pathological grade and clinical stage of lung cancer. METHODS: A total of 115 lung cancer patients diagnosed in our hospital from March 2010 to May 2012 were selected to compare the expression patterns of Oct4 and Sox2 in patients with lung cancer. The relationship between the two factors and the grade and stage of cancer were analyzed . Results: The expression of Oct4 was 42.61% (49) in 115 patients, and the expression rate of Sox2 was 55.65% (64). In 115 cases of lung cancer, Oct4 and Sox2 expression were positive in 26.96% (31), both were negative in 12.17% (14), Oct4 expression was 8.16%, Sox2 expression The 5-year survival rate of patients was 14.06%, the difference was significant. Conclusion: The transcription factors Oct4 and Sox2 are highly expressed in lung cancer lesions and closely related to the occurrence, development and metastasis of cancer lesions, which may be used as an important index to judge the therapeutic effect and prognosis of patients.